While we wait for RVX and Zenith to update their upcoming events pages, here are a few presentations I found on the interwebs between now and mid-April. Zenith should have presented today and RVX presents tomorrow at Biotech Showcase in San Fran.

Feb 8-9, 2016, New York City, NY: BIO CEO and Investor Conference. Resverlogix is presenting

April 19-20, 2016, San Diego, CA: 3rd Annual Epigenetic Inhibitor Discovery: Targeting Histone Methyltransferases, Demethylases and Bromodomains.

4/19/16 10:35 Design and Development of Novel BET Bromodomain Inhibitors

Eric Campeau, Ph.D., PMP, Director of Biology, Zenith Epigenetics

Characterization of ZEN-3694, a novel pan-BET bromodomain inhibitor, and Zenith Epigenetics clinical candidate will be presented, including preclinical activity in relevant models. In addition, examples of next generation BET inhibitors, including compounds that are selective for either the BD1 or BD2 bromodomains of the BET proteins, and irreversible inhibitors of the BET proteins, will be discussed.

April 28, 2016, The New York Academy of Sciences: Epigenetics: Cancer and Beyond

Organizers: Donald McCaffery (Resverlogix Corp), Norman Wong (Resverlogix Corp), George Zavoico (Jones Trading Institutional Services), Sonya Dougal (The New York Academy of Sciences), Caitlin McOmish (The New York Academy of Sciences)

Session Chairs: Dominique Verhelle (Third Rock Ventures), Norman Wong (Resverlogix Corp)

Keynote Speaker: Craig B Thompson (Memorial Sloan Kettering Cancer Center)

Speakers: Eric Campeau (Zenith Epigenetics), Ewelina Kulikowski (Resverlogix Corp), Keiko Ozato (National Institute of Child Health and Human Development), Roberto Pili (Indiana University School of Medicine), Patrick Trojer (Constellation), Christopher Vakoc (Cold Spring Harbor Laboratory)